Replimune Group
$4.6
53
-$0.31-6.31% Tuesday 20:00
Statistics
Day High
5.01
Day Low
4.51
52W High
12.63
52W Low
1.7
Volume
4,707,019
Avg. Volume
-
Mkt Cap
379.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30JulExpected
Expected EPS
-0.633333
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-494.59MNet Income
Analyst Ratings
5Average Price Target
The highest estimate is 14.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy 14%
Hold 57%
Sell 29%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow REPL. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap183.12B
Merck
MRK
Mkt Cap302.33B
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
Gilead Sciences
GILD
Mkt Cap166.82B
Novavax
NVAX
Mkt Cap1.51B
Iovance Biotherapeutics
IOVA
Mkt Cap1.84B
Pfizer
PFE
Mkt Cap147.62B
About
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Show more...
CEO
Dr. Sushil Patel Ph.D.
Employees
479
Country
United States
ISIN
US76029N1063
Listings
0 Comments
Share your thoughts
FAQ
What is Replimune Group stock price today?▼
The current price of REPL is $4.6 USD — it has decreased by -6.31% in the past 24 hours. Watch Replimune Group stock price performance more closely on the chart.
What is Replimune Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Replimune Group stocks are traded under the ticker REPL.
Is Replimune Group stock price growing?▼
REPL stock has fallen by -10.85% compared to the previous week, the month change is a +71.64% rise, over the last year Replimune Group has showed a -45.37% decrease.
What is Replimune Group market cap?▼
Today Replimune Group has the market capitalization of 379.84M
When is the next Replimune Group earnings date?▼
Replimune Group is going to release the next earnings report on July 30, 2026.
What were Replimune Group earnings last quarter?▼
REPL earnings for the last quarter are -0.77 USD per share, whereas the estimation was -0.76 USD resulting in a -0.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Replimune Group revenue for the last year?▼
Replimune Group revenue for the last year amounts to 0 USD.
What is Replimune Group net income for the last year?▼
REPL net income for the last year is -494.59M USD.
How many employees does Replimune Group have?▼
As of May 27, 2026, the company has 479 employees.
In which sector is Replimune Group located?▼
Replimune Group operates in the Health & Wellness sector.
When did Replimune Group complete a stock split?▼
The last stock split for Replimune Group was on December 01, 2010 with a ratio of 15:1.
Where is Replimune Group headquartered?▼
Replimune Group is headquartered in Woburn, United States.